Search

Your search keyword '"Chandra S. Verma"' showing total 428 results

Search Constraints

Start Over You searched for: Author "Chandra S. Verma" Remove constraint Author: "Chandra S. Verma"
428 results on '"Chandra S. Verma"'

Search Results

1. Desmoplakin CSM models unravel mechanisms regulating the binding to intermediate filaments and putative therapeutics for cardiocutaneous diseases

2. Exploring non-alcohol-based disinfectant: virucidal efficacy of arginine and Zinc chloride against feline calicivirus

3. PARP4 interacts with hnRNPM to regulate splicing during lung cancer progression

4. Author Correction: Design-rules for stapled peptides with in vivo activity and their application to Mdm2/X antagonists

5. Design-rules for stapled peptides with in vivo activity and their application to Mdm2/X antagonists

6. Domain-specific p53 mutants activate EGFR by distinct mechanisms exposing tissue-independent therapeutic vulnerabilities

7. A high‐throughput microfluidic mechanoporation platform to enable intracellular delivery of cyclic peptides in cell‐based assays

8. JNK mediates cell death by promoting the ubiquitination of the apurinic/apyrimidinic endonuclease APE1

9. High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

10. Engineering an autonomous VH domain to modulate intracellular pathways and to interrogate the eIF4F complex

11. PhosIDP: a web tool to visualize the location of phosphorylation sites in disordered regions

12. Decreased GLUT2 and glucose uptake contribute to insulin secretion defects in MODY3/HNF1A hiPSC-derived mutant β cells

13. Targeting codon 158 p53-mutant cancers via the induction of p53 acetylation

14. Disrupting the Dok3–Card9 Interaction with Synthetic Peptides Enhances Antifungal Effector Functions of Human Neutrophils

15. Evaluation of Host Defense Peptide (CaD23)-Antibiotic Interaction and Mechanism of Action: Insights From Experimental and Molecular Dynamics Simulations Studies

16. A common MET polymorphism harnesses HER2 signaling to drive aggressive squamous cell carcinoma

17. Development and application of a transcriptional sensor for detection of heterologous acrylic acid production in E. coli

18. Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

19. The polybasic insert, the RBD of the SARS-CoV-2 spike protein, and the feline coronavirus – evolved or yet to evolve

24. A yeast two-hybrid system for the screening and characterization of small-molecule inhibitors of protein–protein interactions identifies a novel putative Mdm2-binding site in p53

25. Can Glycosylation Mask the Detection of MHC Expressing p53 Peptides by T Cell Receptors?

26. Computational Design of Macrocyclic Binders of S100B(ββ): Novel Peptide Theranostics

27. Incorporation of Putative Helix-Breaking Amino Acids in the Design of Novel Stapled Peptides: Exploring Biophysical and Cellular Permeability Properties

37. Author response for 'A high‐throughput microfluidic mechanoporation platform to enable intracellular delivery of cyclic peptides in cell‐based assays'

38. Data from TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors

39. Supplementary Figures from TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors

40. Supplementary Tables from TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors

41. Activating the p53 anti-cancer pathway by targeting the MDM2/MDMX dimer interface with short peptide segments: a computational peptide design experiment

42. On quantum computing and geometry optimization

43. Design-Rules for Stapled Alpha-Helical Peptides with On-Target In Vivo Activity: Application to Mdm2/X dual antagonists

44. Structome: Exploring the structural neighbourhood of proteins

45. Covalent Rescue of Mutant p53

46. Designer co-beta-peptide copolymer selectively targets resistant and biofilm Gram-negative bacteria

47. Discovery of cell active macrocyclic peptides with on-target inhibition of KRAS signaling†

48. Enrichment of charge-absent regions in phase separated proteins

49. High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

50. Update on the Development of MNK Inhibitors as Therapeutic Agents

Catalog

Books, media, physical & digital resources